Effect of Highly Bioavailable Curcumin on Subjective Tinnitus

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

110 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-01-06

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will assess the effectiveness of highly bioavailable curcumin in suppressing subjective tinnitus based on pre- and post-treatment evaluations using the validated Tinnitus Functional Index (TFI) and Tinnitus Handicap Inventory (THI) surveys.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

AM-101 in the Treatment of Acute Tinnitus 2

NCT01803646

Tinnitus

COMPLETED PHASE3

TNF-α Treatment of Blast-Induced Tinnitus

NCT04066348

Tinnitus, Noise Induced

RECRUITING PHASE2

AM-101 in the Treatment of Acute Tinnitus 3

NCT02040194

Tinnitus

COMPLETED PHASE3

Zinc to Treat Tinnitus in the Elderly

NCT00683644

Tinnitus

COMPLETED PHASE2

Safety and Efficacy of Acupressure Applied Through ForgTin© in Patients With Tinnitus

NCT04623957

Tinnitus, Subjective

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Subjects with severe, subjective tinnitus due to sensorineural hearing loss will complete both TFI and THI surveys prior to starting therapy. Subjects will then be randomized to a treatment or placebo group. The treatment group will be provided with a supply of capsules containing 500 mg of curcumin-phosphatidylcholine combined with 250 mg of boswellia-phosphatidylcholine, which increases curcumin bioavailability. Subjects in the treatment arm will be instructed to take 1 capsule by mouth twice daily for 30 days. Placebo group subjects will be provided with a placebo compound with instructions to take the same number of capsules by mouth for the same period of time. Both the active compound and the placebo will be provided by Smartceuticals, Inc (910 W. Van Buren St. Ste 100-376 Chicago, IL 60607) to the outpatient pharmacy at Ascension Providence Park (Novi, MI), which will be responsible for storage, distribution and tracking. After 30 days, patients will be asked to return bottles to the pharmacy with any unused capsules to confirm and monitor compliance. Placebo and active agent capsules and bottles will be identical in appearance with the exception of a unique alphanumeric code on the bottle label that identifies whether the distributed capsules contain active agent or placebo. This code will be matched to the participating subject by the pharmacy and will be used at the end of the study to determine which treatment arm each subject was in. To facilitate blinding, the master list of alphanumeric codes will be maintained by the manufacturer. At the completion of therapy, subjects from both groups will re-take the TFI and THI.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tinnitus, Subjective

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Subjects will be randomized to a treatment or placebo group after completing both the TFI and THI surveys.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment Group

Subjects will be provided with a supply of capsules containing 500 mg of curcumin-phosphatidylcholine combined with 250 mg of boswellia-phosphatidyl. Subjects will take 1 capsule by mouth twice daily for 30 days.

Group Type EXPERIMENTAL

Curcumin-phosphatidylcholine

Intervention Type BIOLOGICAL

500 mg of curcumin-phosphatidylcholine combined with 250 mg of boswellia-phosphatidyl

Placebo Group

Subjects will be provided with a placebo compound with instructions to take 1 capsule by mouth twice daily for 30 days.

Group Type PLACEBO_COMPARATOR

Placebo capsule

Intervention Type BIOLOGICAL

Placebo capsule

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Curcumin-phosphatidylcholine

500 mg of curcumin-phosphatidylcholine combined with 250 mg of boswellia-phosphatidyl

Intervention Type BIOLOGICAL

Placebo capsule

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Tumeric

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults with subjective tinnitus due to sensorineural hearing loss as determined by routine audiogram.

Exclusion Criteria

* Adults with subjective tinnitus due to another cause
* Sensitivity or allergy to test compounds
* Use of other off-label medications, substances, treatments specifically for tinnitus mitigation (e.g., anti-depressant/anxiety medications, GABA-inhibitors, psychiatric-based interventions/counseling)
* Pregnancy
* Patients taking anticoagulants to minimize risk of drug-drug interactions.

Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No